Trial · NCT05636891
Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis
NCT05636891, Phase 1, Completed, Nanogen Pharmaceutical Biotechnology Joint Stock Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis. Trials, record NCT05636891. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05636891
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis
- NCT number
- NCT05636891
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 43 participants, actual
- Lead sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
- Conditions
- Chronic Kidney Disease
- Interventions
- Stimus
- First posted
- 2022-12-05
- Last updated
- 2025-03-30
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PK parameters comparison between NNG-DEPO and Aranesp®: Cmax | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Serum peak concentrations (Cmax) |
| Primary | PK parameters comparison between NNG-DEPO and Aranesp®: AUC(0, t) | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Area under the curve from 0 to t (AUC 0-t) |
| Secondary | PD parameters comparison between NNG-DEPO and Aranesp®: Cmax of reticulocytes | Assessed predose and at and at 24;48;96;144;240;336 hours postdose | Serum peak concentrations (Cmax) of reticulocytes |
| Secondary | PD parameters comparison between NNG-DEPO and Aranesp®: AUC(0, t) of reticulocytes | Assessed predose and at and at 24;48;96;144;240;336 hours postdose | Area under the curve from 0 to t (AUC 0-t) of reticulocytes |
| Secondary | PD parameters comparison between NNG-DEPO and Aranesp®: Tmax of reticulocytes | Assessed predose and at and at 24;48;96;144;240;336 hours postdose | Time for the drug to reach peak concentration (Tmax) of reticulocytes |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®:Tmax | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Time for the drug to reach peak concentration (Tmax) |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®: AUC(0,∞) | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Area under the curve from 0 to ∞ (AUC0-∞) |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®:T1/2 | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Half-life (T1/2) |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®: CL/F | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | CL/F |
| Secondary | PK parameters comparison between NNG-DEPO and Aranesp®:Vz/F | IV:Assessed predose and at 0.25; 0.5; 4;12;24;48;96;144;240;336 hours postdose/ SC: Assessed predose and at 4;12;24;48;96;144;240;336 hours postdose | Vz/F |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05636891
GET https://conductscience.org/api/trials/v1/NCT05636891/registered